Ovarian Cancer
Conditions
Keywords
recurrent ovarian epithelial cancer, stage I ovarian epithelial cancer, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer
Brief summary
RATIONALE: Measuring the amount of prostaglandin metabolite in urine samples and studying tissue samples in the laboratory from patients with ovarian cancer may help doctors identify and learn more about biomarkers related to ovarian cancer and may help the study of cancer in the future. PURPOSE: This laboratory study is measuring the amount of prostaglandin metabolite in urine samples from patients with ovarian cancer.
Detailed description
OBJECTIVES: * Determine the level of prostaglandin E\_2 metabolite (PGE-M) in 24-hour urine samples collected prior to surgery or chemotherapy from patients with ovarian cancer. * Determine cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression by western blot and immunohistochemistry (IHC) in ovarian tumor tissue samples and matched normal ovarian tissue samples, if available, from these patients. * Correlate urine PGE-M levels with corresponding tissue COX-1 and COX-2 levels in urine and tissue samples from these patients. OUTLINE: This is a pilot study. Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of prostaglandin E\_2 metabolite (PGE-M). Patients also undergo assessment of tissue obtained at the time of surgery, including ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for cyclooxygenase-1 and cyclooxygenase-2 expression.
Interventions
GENETICprotein expression analysis
protein expression analysis
OTHERimmunohistochemistry
immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
Sponsors
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
17 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of known or suspected ovarian cancer * Age greater than 17 years
Exclusion criteria
* Pregnant or nursing * Taking steroids or non-steroidal anti-inflammatory drugs (NSAIDs) on a regular basis. PRIOR CONCURRENT THERAPY: * No concurrent chronic use of steroids or NSAIDs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prostaglandin E2 metabolite (PGE-M) levels in 24-hour urine samples | Pre-surgical or chemotherapeutic treatment, over a 24-hour duration | Patients will be collect their urine for 24 hours before they undergo any surgery or chemotherapy. Researchers will measure the amount of PGE-M in the urine. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| COX-1 and COX-2 expression in ovarian tumor tissue and non-malignant tissue | Day of surgery | COX-1 and COX-2 expression will be measured in samples of patients' malignant ovarian samples and matched non-malignant samples (the latter if available). |
| Correlation of urine PGE-M levels with tissue COX-1 and COX-2 levels | After patients' surgery | Patients' levels of urine PGE-M will be compared and contrasted with their levels of COX-1 and COX-2 in ovarian tumor tissue |
Outcome results
None listed